CHRISTOPHER JOHN KENNEY - 23 Aug 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Medical Officer
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
23 Aug 2021
Net transactions value
$0
Form type
4
Filing time
25 Aug 2021, 16:12:29 UTC
Next filing
21 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 23 Aug 2021 Common Shares 150,000 $16.64 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.